Pneumococcal capsular saccharide conjugate vaccine

Abstract

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.

1 - 43 . (canceled) 
     
     
         44 . An immunogenic composition comprising a multivalent  Streptococcus pneumoniae  vaccine comprising ten or more capsular saccharide conjugates from different serotypes, wherein the composition comprises 22F capsular saccharide conjugated to a carrier protein and at least one capsular saccharide conjugated to PhtD via a linker. 
     
     
         45 . (canceled) 
     
     
         46 . The immunogenic composition of  claim 44  wherein the linker is attached to the carrier protein by carbodiimide chemistry. 
     
     
         47 . The immunogenic composition of  claim 44  wherein the 22F saccharide is conjugated to the carrier protein via a linker using 1cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) chemistry. 
     
     
         48 . The immunogenic composition of  claim 44 , wherein the ratio of carrier protein to 22F saccharide is between 5:1 and 1:5 (w/w). 
     
     
         49 - 54 . (canceled) 
     
     
         55 . The immunogenic composition of  claim 44 , wherein the average size of the 22F saccharide is above 100 kDa 
     
     
         56 - 74 . (canceled) 
     
     
         75 . The immunogenic composition of  claim 44  which further comprises one or more unconjugated or conjugated  S pneumoniae  proteins. 
     
     
         76 . (canceled) 
     
     
         77 . The immunogenic composition of  claim 75  wherein said one or more  S. pneumoniae  proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133. 
     
     
         78 - 82 . (canceled) 
     
     
         83 . The immunogenic composition according to  claim 44  which further comprises an adjuvant. 
     
     
         84 - 99 . (canceled) 
     
     
         100 . A vaccine comprising the immunogenic composition of  claim 44  and a pharmaceutically acceptable excipient. 
     
     
         101 . A process for making the vaccine according to  claim 100  which comprises the step of mixing the immunogenic composition of  claim 44  with a pharmaceutically acceptable excipient. 
     
     
         102 - 130 . (canceled) 
     
     
         131 . A method of preventing an elderly human host from having a pneumococcal disease caused by  Streptococcus pneumoniae  serotype 22F infection comprising administering to an infant host an-immunoprotective dose of the immunogenic composition of  claim 44 . 
     
     
         132 . The method of  claim 131 , wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD). 
     
     
         133 . The method of  claim 131 , wherein the disease is exacerbations of chronic obstructive pulmonary disease (COPD). 
     
     
         134 - 136 . (canceled) 
     
     
         137 . The immunogenic composition of  claim 44 , further comprising conjugates of  S. pneumoniae  capsular saccharides selected from serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
     
     
         138 . The immunogenic composition of  claim 44 , further comprising conjugates of  S. pneumoniae  capsular saccharides 1, 4, 5, 6B, 7F, 9V, 14, 18C and 23F. 
     
     
         139 . The immunogenic composition of  claim 44 , further comprising conjugates of  S. pneumoniae  capsular saccharides 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, and 23F. 
     
     
         140 . The immunogenic composition of  claim 44 , further comprising conjugates of  S. pneumoniae  capsular saccharides 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, and 23F 
     
     
         141 . The immunogenic composition of  claim 44 , the saccharide conjugate has a ratio of PhtD to saccharide in the conjugate is between 6:1 and 2:1 (w/w). 
     
     
         142 . The immunogenic composition of  claim 44 , wherein the saccharide conjugate has a ratio of PhtD to saccharide in the conjugate greater than (i.e. contains a larger proportion of PhtD) 2.0:1, 2.5:1, 3.0:1, 3.5:1 or 4.0:1.